Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

David Loren

Gastroenterology Phila, PA Medical Doctor

NPI 1508825316 CMS profile 204451

132 S 10Th St, 480 Main Building, Phila, PA 19107

Open in the dashboard

General payments

$132,114

310 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, David Loren of Phila, PA is reported in the CMS Open Payments database as having received $132,114 across 310 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 96th percentile of Gastroenterology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,987 20
2024 General $18,394 39
2023 General $27,024 50
2022 General $23,462 57
2021 General $13,611 49
2020 General $10,889 26
2019 General $36,746 69

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • David Loren
  • Gastroenterology median
  • Middle half of Gastroenterology
  • National median

In program year 2025, general payments to David Loren were reported at $1,987. Among 13,050 Gastroenterology profiles paid that year, the median was $639 and the middle half received between $167 and $1,700.

Show as a table
Year David Loren Gastroenterology median Middle half National median
2019 $36,746 $417 $126–$1,100 $163
2020 $10,889 $224 $74–$624 $114
2021 $13,611 $352 $106–$1,054 $132
2022 $23,462 $448 $129–$1,270 $149
2023 $27,024 $533 $150–$1,390 $160
2024 $18,394 $605 $160–$1,606 $164
2025 $1,987 $639 $167–$1,700 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Boston Scientific Corporation $59,643 166 payments
  2. Olympus Corporation $27,400 29 payments
  3. Olympus America Inc. $21,492 28 payments
  4. Olympus Latin America, Inc. $14,879 24 payments
  5. Pinnacle Biologics, Inc $3,500 1 payment
  6. Olympus Corporation of the Americas $1,892 10 payments
  7. FUJIFILM Medical Systems USA, Inc. $1,535 34 payments
  8. Ambu Inc. $530 2 payments
  9. Medtronic, Inc. $382 3 payments
  10. AngioDynamics, Inc. $192 1 payment
  11. Other $670 12 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $59,130 35 payments
  2. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $50,103 24 payments
  3. Travel and Lodging $12,322 54 payments
  4. Food and Beverage $10,048 196 payments
  5. Entertainment $511 1 payment
Products named General payments · program years 2019–2025
  1. General - Therapies $21,291 21 payments
  2. Olympus Biliary Devices $19,101 27 payments
  3. Olympus EndoTherapy Accessories $8,986 9 payments
  4. Olympus EUS Devices $8,086 12 payments
  5. Axios Axios_ENDO $4,907 8 payments
  6. SPYGLASS $4,862 4 payments
  7. AXIOS Pain Management $4,565 8 payments
  8. Olympus Duodenoscopes $4,120 4 payments
  9. Photofrin $3,500 1 payment
  10. EVIS EXERA III DUODENOVIDEOSCOPE $2,614 1 payment
  11. Other $13,473 170 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 4 drugs

Part D claims

74

Median for Gastroenterology: 569

Drug cost

$23,172

Median for Gastroenterology: $104,976

Branded share of claims

14.9%

Median for Gastroenterology: 31.8%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Creon Lipase/Protease/Amylase Brand 11 $22,539
Omeprazole Generic 23 $369
Pantoprazole Sodium Generic 19 $135
Levofloxacin Generic 21 $128

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 14,294 Part D prescribers listed as Gastroenterology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 65 billing codes

Paid by Medicare

$74,676

Medicare's payments for the services billed

Medicare patients

291

Average age 73

Services billed

687

160 women, 131 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 53%
Ischemic heart disease 37%
Diabetes 35%
Cancer 34%
Chronic kidney disease 27%
COPD 25%
Depression 25%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

310 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Gastroenterology in Pennsylvania

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record